Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.

•  
• Overview
•  
• Research
•  
• Identity
•  
• Additional Document Info
•  
• View All
•  

Overview

authors

• Dejan Jakimovski MD, PhD
• Weinstock-Guttman, Bianca
• Ramanathan, Murali
• Kolb, Channa
• Hojnacki, David
• Minagar, Alireza
• Zivadinov, Robert

publication date

• January 1, 2017

published in

• Expert opinion on biological therapy  Journal

has subject area

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antigens, CD20
• B-Lymphocytes
• Clinical Trials as Topic
• Half-Life
• Humans
• Immunologic Factors
• Multiple Sclerosis, Chronic Progressive
• Multiple Sclerosis, Relapsing-Remitting
• Treatment Outcome

Research

Keywords

• B-cell therapy
• Ocrelizumab
• multiple sclerosis
• primary-progressive
• relapsing-remitting

Identity

Digital Object Identifier (DOI)

• https://doi.org/10.1080/14712598.2017.1347632

PubMed ID

• 28658986

Additional Document Info

start page

• 1163

end page

• 1172

volume

• 17

issue

• 9